Quick Answer
Grace Therapeutics, Inc. reported Shares Outstanding of 9.40 million shares for fiscal year 2024.
Grace Therapeutics, Inc. Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2024 | 9.40M | +26.4% |
| 2023 | 7.44M | -83.2% |
| 2022 | 44.29M | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | 15.47M | +52.6% | +9.5% |
| September 30, 2025 | 14.13M | — | +2.2% |
| June 30, 2025 | 13.83M | — | +0.8% |
| March 31, 2025 | 13.72M | +45.9% | +35.3% |
| December 31, 2024 | 10.14M | — | +7.9% |
| March 31, 2024 | 9.40M | +26.4% | +26.4% |
| June 30, 2023 | 7.44M | — | +0.0% |
| March 31, 2023 | 7.44M | — | — |
- Grace Therapeutics, Inc. showed an increase of +26.4% in Shares Outstanding compared to the prior fiscal year.
- Over the 2022–2024 period, Grace Therapeutics, Inc.’s shares outstanding has declined by 78.8% (from 44.29 million shares to 9.40 million shares).
- The most recent figure is from Grace Therapeutics, Inc.’s fiscal year 2023 report (Form 10-K), filed with the SEC on June 21, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: